Rafael G. Amado

9.3k total citations · 3 hit papers
57 papers, 6.7k citations indexed

About

Rafael G. Amado is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Rafael G. Amado has authored 57 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 14 papers in Immunology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Rafael G. Amado's work include Colorectal Cancer Treatments and Studies (22 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (12 papers). Rafael G. Amado is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (12 papers). Rafael G. Amado collaborates with scholars based in United States, Belgium and Italy. Rafael G. Amado's co-authors include Marc Peeters, Eric Van Cutsem, Salvatore Siena, Michael Wolf, Daniel J. Freeman, Robert Radinsky, Todd Juan, Scott D. Patterson, Sid Suggs and Robert Sikorski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Biotechnology.

In The Last Decade

Rafael G. Amado

57 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 2.4k citations Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology profile →
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

2007 1.5k citations Eric Van Cutsem, Marc Peeters et al. Journal of Clinical Oncology profile →
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 644 citations J. Randolph Hecht, Rafael G. Amado et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rafael G. Amado United States	21	5.0k	2.3k	1.5k	1.4k	1.2k	57	6.7k
Allen Lee Cohn United States	38	4.7k 0.9×	2.4k 1.0×	1.0k 0.7×	1.2k 0.9×	1.5k 1.3×	159	6.9k
Alain Hendlisz Belgium	33	5.2k 1.0×	2.0k 0.9×	1.4k 0.9×	1.2k 0.9×	1.1k 0.9×	209	7.1k
Sebastian Stintzing Germany	40	4.4k 0.9×	2.0k 0.9×	1.6k 1.0×	1.1k 0.8×	994 0.9×	328	6.0k
Tae Won Kim South Korea	44	5.1k 1.0×	2.5k 1.1×	1.5k 1.0×	884 0.6×	1.3k 1.1×	296	7.5k
Michael Schlichting Germany	16	5.2k 1.0×	2.0k 0.9×	1.6k 1.0×	1.4k 1.0×	927 0.8×	43	6.2k
Kelly S. Oliner United States	28	4.6k 0.9×	2.6k 1.1×	1.6k 1.1×	1.3k 1.0×	1.3k 1.1×	68	6.4k
Corina E. Dutcus United States	34	3.7k 0.7×	2.4k 1.0×	879 0.6×	1.2k 0.9×	1.4k 1.2×	110	7.4k
Christiane Langer United States	13	4.6k 0.9×	2.0k 0.9×	1.5k 1.0×	962 0.7×	1.1k 1.0×	26	5.8k
Astrid Lièvre France	29	4.4k 0.9×	2.2k 1.0×	1.7k 1.1×	698 0.5×	1.4k 1.2×	175	6.2k
Chiara Cremolini Italy	40	6.1k 1.2×	2.3k 1.0×	2.1k 1.4×	1.7k 1.2×	1.6k 1.4×	335	7.6k

Countries citing papers authored by Rafael G. Amado

Since Specialization

Citations

This map shows the geographic impact of Rafael G. Amado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael G. Amado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael G. Amado more than expected).

Fields of papers citing papers by Rafael G. Amado

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafael G. Amado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael G. Amado. The network helps show where Rafael G. Amado may publish in the future.

Co-authorship network of co-authors of Rafael G. Amado

This figure shows the co-authorship network connecting the top 25 collaborators of Rafael G. Amado. A scholar is included among the top collaborators of Rafael G. Amado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael G. Amado. Rafael G. Amado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lam, Vincent K., David S. Hong, John V. Heymach, et al.. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology. 29. viii731–viii731. 2 indexed citations

Lam, Vincent K., David S. Hong, John V. Heymach, et al.. (2018). Initial safety assessment of MAGE-A10^c796TCR T-cells in two clinical trials.. Journal of Clinical Oncology. 36(15_suppl). 3056–3056. 8 indexed citations

Mackall, Crystal L., Sandra P. D’Angelo, Stephan A. Grupp, et al.. (2016). Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043). Annals of Oncology. 27. vi368–vi368. 2 indexed citations

Suttle, A. Benjamin, Howard Ball, Mathiéu Molimard, et al.. (2014). Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. British Journal of Cancer. 111(10). 1909–1916. 147 indexed citations

Britten, Carolyn D., Antoinette S. Gomes, Zev A. Wainberg, et al.. (2012). Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study. BMC Cancer. 12(1). 16–16. 40 indexed citations

Kumar, Rakesh & Rafael G. Amado. (2010). Predictive Genomic Biomarkers. Current topics in microbiology and immunology. 355. 173–188. 4 indexed citations

Peeters, Marc, Salvatore Siena, Eric Van Cutsem, et al.. (2009). Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 115(7). 1544–1554. 106 indexed citations

Amado, Rafael G., Michael Wolf, Marc Peeters, et al.. (2008). Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(10). 1626–1634. 2400 indexed citations breakdown →

Amado, Rafael G., Melissa M. Wolf, Daniel Freeman, et al.. (2008). Association of KRAS mutational status and efficacy of panitumumab monotherapy for the treatment (tx) of metastatic colorectal cancer (mCRC): results of pooled data from 4 clinical studies.. Annals of Oncology. 19(8). 126–126. 5 indexed citations

10.

Hecht, J. Randolph, Amita Patnaik, Jordan Berlin, et al.. (2007). Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 110(5). 980–988. 158 indexed citations

11.

Peeters, Marc, Eric Van Cutsem, Jordan Berlin, et al.. (2007). Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. Journal of Clinical Oncology. 25(18_suppl). 4138–4138. 17 indexed citations

12.

Berlin, Jordan, Eric Van Cutsem, Marc Peeters, et al.. (2007). Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. Journal of Clinical Oncology. 25(18_suppl). 4134–4134. 23 indexed citations

13.

Amado, Rafael G., Michael Wolf, Daniel J. Freeman, et al.. (2007). 7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. European Journal of Cancer Supplements. 5(6). 8–8. 17 indexed citations

14.

Jakobovits, Aya, Rafael G. Amado, Xiaodong Yang, Lorin Roskos, & Gisela Schwab. (2007). From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nature Biotechnology. 25(10). 1134–1143. 153 indexed citations

15.

Berlin, Jordan, James Posey, Simon Tchekmedyian, et al.. (2007). Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 6(6). 427–432. 79 indexed citations

16.

Österborg, Anders, Dusan Kotasek, Jana Prausová, et al.. (2006). A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks. Journal of Clinical Oncology. 24(18_suppl). 8626–8626. 3 indexed citations

17.

Canon, Jean-Luc, Johan Vansteenkiste, G. Bodoky, et al.. (2006). Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia. JNCI Journal of the National Cancer Institute. 98(4). 273–284. 83 indexed citations

18.

Lu, David, Nam Chol Yu, Steven S. Raman, et al.. (2005). Radiofrequency Ablation of Hepatocellular Carcinoma: Treatment Success as Defined by Histologic Examination of the Explanted Liver. Radiology. 234(3). 954–960. 297 indexed citations

19.

Amado, Rafael G., et al.. (2002). Low-dose trimetrexate glucuronate and protracted5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer. Annals of Oncology. 13(4). 582–588. 3 indexed citations

20.

Amado, Rafael G., Geoff Symonds, Beth D. Jamieson, et al.. (1998). Effects of Megakaryocyte Growth and Development Factor on Survival and Retroviral Transduction of T Lymphoid Progenitor Cells. Human Gene Therapy. 9(2). 173–183. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact